Search This Blog

Wednesday, March 25, 2026

Anavex withdraws EU marketing application for blarcamesine in early Alzheimer’s

 

as EMA panel signals no positive opinion

  • Application covered blarcamesine as an add-on treatment for early Alzheimer’s; EMA’s CHMP declined to give positive opinion now.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)